Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) had its Buy rating reiterated by Wells Fargo & Co

Analyst Ratings For Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL)

Story continues below

Today, Wells Fargo & Co reiterated its Buy rating on Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL).

There are 4 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) is Buy with a consensus target price of $40.00 per share, a potential 0.18% upside.

Some recent analyst ratings include

  • 11/29/2018-Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) had its Buy rating reiterated by Wells Fargo & Co
  • 11/2/2018-Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) had its Buy rating reiterated by HC Wainwright with a $45.00 price target
  • 7/26/2018-Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) has coverage initiated with a Neutral rating
  • 7/17/2018-Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) has coverage initiated with a Outperform rating
  • 7/17/2018-Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) has coverage initiated with a Buy rating and $37.00 price target


    About Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL)
    Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

    Recent Trading Activity for Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL)
    Shares of Autolus Therapeutics Ltd – ADR closed the previous trading session at 38,19 up +1,19 3,22 % with 35.57 shares trading hands.

    An ad to help with our costs